BlackBerry Patent Lawsuit Rises Again; NTP Responds to Patent Office Rejections
Case on Obviousness Jurisprudence Gains Support — Microsoft Files Amicus Brief
Prima Tek II v. Polypap
CAFC Finds Jurisdiction To Hear Declaratory Judgment Issues After Patentee Files Covenant Not To Sue
Who’s Your Inventor?: Contradictory Declarations Leads to Summary Judgment Reversal
Supreme Court to Reexamine the Interplay Between Patents and Unlawful Tying Agreements
Will US Courts Adjudicate Foreign Patents or Will Comity Prevail?
CAFC: Patent Laws Preempt Unjust Enrichment Claim
SmithKline Beecham v. Apotex: A Conclusion?
Seed License Agreement Does Not Implicate Plant Variety Protection Act
PTO Board: Disclosure of Sequence Enables at least 5% of Natural Variance.
Ex parte Bandman, No. 2004-2319, (BPAI 2005)
By Donald Zuhn
In an appeal from a final rejection, the PTO Board reversed rejections based on both the written description and enablement requirements of 35 U.S.C. § 112, first paragraph, and entered a new ground of rejection under 35 U.S.C. § 112, second paragraph one of the claims. (U.S. Application No. 09/915,694).
Pointedly, the Board found that claims directed to a naturally occurring amino acid (or polynucleotide) sequence at least 95% identical to the disclosed amino acid (or polynucleotide) sequence were enabled and met the written description requirement.